Array Biopharma (ARRY) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $5.33 --0%
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
SENEA, XFOR, MG, More
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
SENEA, XFOR, MG, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.22), in-line with the analyst estimate of ($0.22). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $33.28 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ACM Research (ACMR) Tops Q3 EPS by 6c ; Offers Guidance
- EPAM Systems (EPAM) Tops Q3 EPS by 11c, Beats on Revenue; Offers FY26 EPS Guidance
- Lemonade (LMND) Tops Q3 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
